{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:11:38Z","timestamp":1794978698951,"version":"4.9.1"},"reference-count":127,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD), represented by Crohn\u2019s disease (CD) and ulcerative\ncolitis (UC), is a chronic inflammatory disorder of the gastrointestinal tract (GIT) characterized by\nchronic relapsing intestinal inflammation, abdominal pain, cramping, loss of appetite, fatigue, diarrhoea,\nand weight loss. Although the etiology of IBD remains unclear, it is believed to be an interaction\nbetween genes, and environmental factors, such as an imbalance of the intestinal microbiota,\nchanging food habits, an ultra-hygiene environment, and an inappropriate immune system. The development\nof novel effective therapies is stymied by a lack of understanding of the aetiology of\nIBD. The current therapy involves the use of aminosalicylates, immunosuppressants, and corticosteroids\nthat can effectively manage symptoms, induce and sustain remission, prevent complications,\nmodify the course of the disease, provide diverse treatment options, showcase advancements\nin biologic therapies, and enhance the overall quality of life. However, the efficacy of current therapy\nis overshadowed by a plethora of adverse effects, such as loss of weight, mood swings, skin issues,\nloss of bone density, higher vulnerability to infections, and elevated blood pressure. Biologicals,\nlike anti-tumour necrosis factor agents, can stimulate an autoimmune response in certain individuals\nthat may diminish the effectiveness of the medication over time, necessitating a switch to\nalternative treatments. The response of IBD patients to current drug therapy is quite varied, which\ncan lead to disease flares that underlines the urgent need to explore alternative treatment option to\naddress the unmet need of developing new treatment strategies for IBD with high efficacy and fewer\nadverse effects. Drug repurposing is a novel strategy where existing drugs that have already been\nvalidated safe in patients for the management of certain diseases are redeployed to treat other, unindicated\ndiseases. The present narrative review focuses on potential drug candidates that could be repurposed\nfor the management of IBD using on-target and off-target strategies. It covers their preclinical,\nclinical assessment, mechanism of action, and safety profiles, and forecasts their appropriateness\nin the management of IBD. The review presents useful insights into the most promising\ncandidates for repurposing, like anti-inflammatory and anti-apoptotic troxerutin, which has been\nfound to improve the DSS-induced colitis in rats, an antiosteoarthritic drug diacetylrhein that has\nbeen found to have remarkable ameliorating effects on DSS-induced colitis via anti-oxidant and anti-\ninflammatory properties and by influencing both apoptosis and pyroptosis. Topiramate, an antiepileptic\nand anticonvulsant drug, has remarkably decreased overall pathophysiological and histopathological\nevents in the experimental model of IBD in rodents by its cytokine inhibitory action.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0127724328245156231008154045","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T01:34:35Z","timestamp":1697765675000},"page":"234-249","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Application of Drug Repurposing Approach for Therapeutic Intervention\nof Inflammatory Bowel Disease"],"prefix":"10.2174","volume":"19","author":[{"given":"Mohammad Aadil","family":"Bhat","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, UP, Noida,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqra","family":"Usman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, UP, Noida,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneela","family":"Dhaneshwar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai,\nMaharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","volume":"8","author":"Cai Z.","year":"2021","unstructured":"Cai Z.; Wang S.; Li J.; Treatment of inflammatory bowel disease: A comprehensive review. Front Med (Lausanne)  2021,8(December),765474","journal-title":"Front Med (Lausanne)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","volume":"94","author":"Ramos G.P.","year":"2019","unstructured":"Ramos G.P.; Papadakis K.A.; Mechanisms of disease: Inflammatory bowel diseases. Mayo Clin Proc  2019,94(1),155-165","journal-title":"Mayo Clin Proc"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","volume":"369","author":"Baumgart D.C.","year":"2007","unstructured":"Baumgart D.C.; Carding S.R.; Series Gastroenterology 1 Infl ammatory bowel disease : Cause and immunobiology. Lancet  2007,369,1627-1640","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.25122\/jml-2018-0075","volume":"12","author":"Seyedian S.S.","year":"2019","unstructured":"Seyedian S.S.; Nokhostin F.; Malamir M.D.; A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life  2019,12(2),113-122","journal-title":"J Med Life"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.cgh.2006.03.003","volume":"4","author":"Burgmann T.","year":"2006","unstructured":"Burgmann T.; Clara I.; Graff L.; The Manitoba Inflammatory Bowel Disease Cohort Study: Prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol  2006,4(5),614-620","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=6","first-page":"629","volume":"63","author":"Pithadia A.B.","year":"2011","unstructured":"Pithadia A.B.; Jain S.; Treatment of inflammatory bowel disease (IBD). In: Pharmacological reports. Elsevier BV  2011,63,629-42","journal-title":"Elsevier BV"},{"key":"ref=7","author":"Roy S","year":"2018","unstructured":"Roy S; Dhaneshwar S;  Drug repurposing opportunities for inflammatory bowel disease  2018","journal-title":"Drug repurposing opportunities for inflammatory bowel disease"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"Molodecky N.A.","year":"2012","unstructured":"Molodecky N.A.; Soon I.S.; Rabi D.M.;  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology  2012,142(1),46-54.e4","journal-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"Kaplan G.G.","year":"2015","unstructured":"Kaplan G.G.; The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol  2015,12(12),720-727","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11938-018-0175-1","volume":"16","author":"Duijvestein M.","year":"2018","unstructured":"Duijvestein M.; Battat R.; Casteele N.; Novel therapies and treatment strategies for patients with inflammatory bowel disease. Curr Treat Options Gastroenterol  2018,16(1),129-146","journal-title":"Curr Treat Options Gastroenterol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.pcl.2011.06.007","volume":"58","author":"Szigethy E.","year":"2011","unstructured":"Szigethy E.; McLafferty L.; Goyal A.; Inflammatory bowel disease. Pediatr Clin North Am  [x-xi.]2011,58(4),903-920","journal-title":"Pediatr Clin North Am"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1756284819853208","author":"Sabino J.","year":"2019","unstructured":"Sabino J.; Verstockt B.; Vermeire S.; Ferrante M.; New biologics and small molecules in inflammatory bowel disease: An update. Therap Adv Gastroenterol  2019,12","journal-title":"Therap Adv Gastroenterol"},{"key":"ref=13","first-page":"19","author":"McDonald C.","year":"2013","unstructured":"McDonald C.; Fiocchi C.;  Pathophysiology of inflammatory bowel disease  2013,19-30","journal-title":"Pathophysiology of inflammatory bowel disease"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.crohns.2014.05.008","volume":"8","author":"Childers R.E.","year":"2014","unstructured":"Childers R.E.; Eluri S.; Vazquez C.; Weise R.M.; Bayless T.M.; Hutfless S.; Family history of inflammatory bowel disease among patients with ulcerative colitis: A systematic review and meta-analysis. J Crohn\u2019s Colitis  2014,8(11),1480-1497","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"Jostins L.","year":"2012","unstructured":"Jostins L.; Ripke S.; Weersma R.K.; Host\u2013microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature  2012,491(7422),119-124","journal-title":"Nature"},{"key":"ref=16","author":"Guan Q.","year":"2019","unstructured":"Guan Q.; A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019  2019","journal-title":"J Immunol Res 2019"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","volume":"20","author":"Zhang Y.Z.","year":"2014","unstructured":"Zhang Y.Z.; Li Y.Y.; Inflammatory bowel disease: Pathogenesis. World J Gastroenterol  2014,20(1),91-99","journal-title":"World J Gastroenterol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"de Souza H.S.P.","year":"2016","unstructured":"de Souza H.S.P.; Fiocchi C.; Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol  2016,13(1),13-27","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.it.2010.12.007","volume":"32","author":"Shaw M.H.","year":"2011","unstructured":"Shaw M.H.; Kamada N.; Warner N.; Kim Y.G.; Nu\u00f1ez G.; The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation. Trends Immunol  2011,32(2),73-79","journal-title":"Trends Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/ni.1722","volume":"10","author":"Noguchi E.","year":"2009","unstructured":"Noguchi E.; Homma Y.; Kang X.; Netea M.G.; Ma X.; A Crohn\u2019s disease\u2013associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol  2009,10(5),471-479","journal-title":"Nat Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/ng1954","volume":"39","author":"Hampe J.","year":"2007","unstructured":"Hampe J.; Franke A.; Rosenstiel P.; A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet  2007,39(2),207-211","journal-title":"Nat Genet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng2061","volume":"39","author":"Parkes M.","year":"2007","unstructured":"Parkes M.; Barrett J.C.; Prescott N.J.; Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn\u2019s disease susceptibility. Nat Genet  2007,39(7),830-832","journal-title":"Nat Genet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature09782","volume":"469","author":"Levine B.","year":"2011","unstructured":"Levine B.; Mizushima N.; Virgin H.W.; Autophagy in immunity and inflammation. Nature  2011,469(7330),323-335","journal-title":"Nature"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13148-021-01089-3","volume":"13","author":"Hornschuh M.","year":"2021","unstructured":"Hornschuh M.; Wirthgen E.; Wolfien M.; Singh K.P.; Wolkenhauer O.; D\u00e4britz J.; The role of epigenetic modifications for the pathogenesis of Crohn\u2019s disease. Clin Epigenetics  2021,13(1),108","journal-title":"Clin Epigenetics"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","volume":"11","author":"Nishida A.","year":"2018","unstructured":"Nishida A.; Inoue R.; Inatomi O.; Bamba S.; Naito Y.; Andoh A.; Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol  2018,11(1),1-10","journal-title":"Clin J Gastroenterol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"13780","DOI":"10.1073\/pnas.0706625104","volume":"104","author":"Frank D.N.","year":"2007","unstructured":"Frank D.N.; St Amand A.L.; Feldman R.A.; Boedeker E.C.; Harpaz N.; Pace N.R.; Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA  2007,104(34),13780-13785","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.chom.2008.05.001","volume":"3","author":"Peterson D.A.","year":"2008","unstructured":"Peterson D.A.; Frank D.N.; Pace N.R.; Gordon J.I.; Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe  2008,3(6),417-427","journal-title":"Cell Host Microbe"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1053\/j.gastro.2013.07.050","volume":"145","author":"Ananthakrishnan A.N.","year":"2013","unstructured":"Ananthakrishnan A.N.; Khalili H.; Konijeti G.G.; A prospective study of long-term intake of dietary fiber and risk of Crohn\u2019s disease and ulcerative colitis. Gastroenterology  2013,145(5),970-977","journal-title":"Gastroenterology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/ajg.2011.44","volume":"106","author":"Hou J.K.","year":"2011","unstructured":"Hou J.K.; Abraham B.; El-Serag H.; Dietary intake and risk of developing inflammatory bowel disease: A systematic review of the literature. Am J Gastroenterol  2011,106(4),563-573","journal-title":"Am J Gastroenterol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1136\/gutjnl-2013-305304","volume":"63","author":"Ananthakrishnan A.N.","year":"2014","unstructured":"Ananthakrishnan A.N.; Khalili H.; Konijeti G.G.; Long-term intake of dietary fat and risk of ulcerative colitis and Crohn\u2019s disease. Gut  2014,63(5),776-784","journal-title":"Gut"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/0003-4819-156-5-201203060-00007","volume":"156","author":"Ashwin N.A.","year":"2012","unstructured":"Ashwin N.A.; Higuchi L.M.; Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn. Ann Intern Med  2012,156(5),350-359","journal-title":"Ann Intern Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3109\/00365521.2014.966753","volume":"50","author":"Kvasnovsky C.L.","year":"2015","unstructured":"Kvasnovsky C.L.; Aujla U.; Bjarnason I.; Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol  2015,50(3),255-263","journal-title":"Scand J Gastroenterol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev.physiol.010908.163145","volume":"71","author":"van der Flier L.G.","year":"2009","unstructured":"van der Flier L.G.; Clevers H.; Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol  2009,71(1),241-260","journal-title":"Annu Rev Physiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.gastro.2006.04.020","volume":"131","author":"Van der Sluis M.","year":"2006","unstructured":"Van der Sluis M.; De Koning B.A.E.; De Bruijn A.C.J.M.; Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology  2006,131(1),117-129","journal-title":"Gastroenterology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/gut.2009.206466","volume":"60","author":"Fritz T.","year":"2011","unstructured":"Fritz T.; Niederreiter L.; Adolph T.; Blumberg R.S.; Kaser A.; Crohn\u2019s disease: NOD2, autophagy and ER stress converge. Gut  2011,60(11),1580-1588","journal-title":"Gut"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4535194","author":"Tian T","year":"2017","unstructured":"Tian T; Wang Z; Zhang J;  Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies Oxid Med Cell Longev 2017  2017","journal-title":"Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies Oxid Med Cell Longev 2017"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1097\/MIB.0b013e318281f54e","volume":"19","author":"Brazil J.C.","year":"2013","unstructured":"Brazil J.C.; Louis N.A.; Parkos C.A.; The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease. Inflamm Bowel Dis  2013,19(7),1556-1565","journal-title":"Inflamm Bowel Dis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","volume":"30","author":"Zheng D.","year":"2020","unstructured":"Zheng D.; Liwinski T.; Elinav E.; Interaction between microbiota and immunity in health and disease. Cell Res  2020,30(6),492-506","journal-title":"Cell Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.molmed.2009.03.002","volume":"15","author":"Zenewicz L.A.","year":"2009","unstructured":"Zenewicz L.A.; Antov A.; Flavell R.A.; CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med  2009,15(5),199-207","journal-title":"Trends Mol Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","volume":"52","author":"Fujino S.","year":"2003","unstructured":"Fujino S.; Andoh A.; Bamba S.; Increased expression of interleukin 17 in inflammatory bowel disease. Gut  2003,52(1),65-70","journal-title":"Gut"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.it.2013.08.002","volume":"34","author":"Biancheri P.","year":"2013","unstructured":"Biancheri P.; Powell N.; Monteleone G.; Lord G.; MacDonald T.T.; The challenges of stratifying patients for trials in inflammatory bowel disease. Trends Immunol  2013,34(11),564-571","journal-title":"Trends Immunol"},{"key":"ref=42","first-page":"30","volume":"71","author":"Neurath M.F.","year":"2000","unstructured":"Neurath M.F.; Sch\u00fcrmann G.; Immunopathogenesis of inflammatory bowel diseases. Chirurg  2000,71(1),30-40","journal-title":"Chirurg"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/MOG.0b013e328311f26e","volume":"24","author":"Boden E.K.","year":"2008","unstructured":"Boden E.K.; Snapper S.B.; Regulatory T cells in inflammatory bowel disease. Curr Opin Gastroenterol  2008,24(6),733-741","journal-title":"Curr Opin Gastroenterol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.addr.2007.07.003","volume":"59","author":"Wirtz S.","year":"2007","unstructured":"Wirtz S.; Neurath M.; Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev  2007,59(11),1073-1083","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3748\/wjg.14.4280","volume":"14","author":"Sanchez-Munoz F.","year":"2008","unstructured":"Sanchez-Munoz F.; Dominguez-Lopez A.; Yamamoto-Furusho J-K.; Role of cytokines in inflammatory bowel disease. World J Gastroenterol  2008,14(27),4280-4288","journal-title":"World J Gastroenterol"},{"key":"ref=46","first-page":"p1156","author":"Paul A.","year":"2021","unstructured":"Paul A.; Anandabaskar N.; Mathaiyan J.; Raj G.M.; Introduction to Basics of Pharmacology and Toxicology: Volume 2: Essentials of Systemic Pharmacology:  2021,p1156"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.3390\/nano10122460","volume":"10","author":"Jacob E.M.","year":"2020","unstructured":"Jacob E.M.; Borah A.; Pillai S.C.; Kumar D.S.; Inflammatory bowel disease: The emergence of new trends in lifestyle and nanomedicine as the modern tool for pharmacotherapy. Nanomaterials (Basel)  2020,10(12),2460","journal-title":"Nanomaterials (Basel)"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"Ord\u00e1s I.","year":"2012","unstructured":"Ord\u00e1s I.; Eckmann L.; Talamini M.; Baumgart D.C.; Sandborn W.J.; Ulcerative colitis. Lancet  2012,380(9853),1606-1619","journal-title":"Lancet"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/DCR.0000000000000030","volume":"57","author":"Ross H.","year":"2014","unstructured":"Ross H.; Steele S.R.; Varma M.; Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum  2014,57(1),5-22","journal-title":"Dis Colon Rectum"},{"key":"ref=50","first-page":"151","author":"Askelof E","year":"1992","unstructured":"Askelof E; Helander S; Mechanism of action of 5-arninosalicylic acid. 1992  1992,151-65"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1111\/j.1572-0241.2000.03360.x","volume":"95","author":"Bantel H.","year":"2000","unstructured":"Bantel H.; Berg C.; Vieth M.; Stolte M.; Kruis W.; Schulze-Osthoff K.; Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol  2000,95(12),3452-3457","journal-title":"Am J Gastroenterol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1084\/jem.20041948","volume":"201","author":"Rousseaux C.","year":"2005","unstructured":"Rousseaux C.; Lefebvre B.; Dubuquoy L.; Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator\u2013activated receptor-\u03b3. J Exp Med  2005,201(8),1205-1215","journal-title":"J Exp Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1756283X11405250","volume":"4","author":"Williams C.","year":"2011","unstructured":"Williams C.; Panaccione R.; Ghosh S.; Rioux K.; Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol  2011,4(4),237-248","journal-title":"Therap Adv Gastroenterol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/ibd.20099","volume":"13","author":"Gisbert J.P.","year":"2007","unstructured":"Gisbert J.P.; Gonz\u00e1lez-Lama Y.; Mat\u00e9 J.; 5-Aminosalicylates and renal function in inflammatory bowel disease. Inflamm Bowel Dis  2007,13(5),629-638","journal-title":"Inflamm Bowel Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jcol.2015.08.006","volume":"35","author":"Teixeira F.V.","year":"2015","unstructured":"Teixeira F.V.; Hosne R.S.; Sobrado C.W.; Management of ulcerative colitis: A clinical update. J Coloproctol (Rio J)  2015,35(4),230-237","journal-title":"J Coloproctol (Rio J)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"Mowat C.","year":"2011","unstructured":"Mowat C.; Cole A.; Windsor A.; Guidelines for the management of inflammatory bowel disease in adults. Gut  2011,60(5),571-607","journal-title":"Gut"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"Oray M.","year":"2016","unstructured":"Oray M.; Abu Samra K.; Ebrahimiadib N.; Meese H.; Foster C.S.; Long-term side effects of glucocorticoids. Expert Opin Drug Saf  2016,15(4),457-465","journal-title":"Expert Opin Drug Saf"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","volume":"10","author":"Brattsand R.","year":"1996","unstructured":"Brattsand R.; Linden M.; Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther  1996,10(Suppl. 2),81-90","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","volume":"42","author":"Ramamoorthy S.","year":"2016","unstructured":"Ramamoorthy S.; Cidlowski J.A.; Corticosteroids. Rheum Dis Clin North Am  [vii.]2016,42(1),15-31","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11916-012-0273-z","volume":"16","author":"Leppert W.","year":"2012","unstructured":"Leppert W.; Buss T.; The role of corticosteroids in the treatment of pain in cancer patients. Curr Pain Headache Rep  2012,16(4),307-313","journal-title":"Curr Pain Headache Rep"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1038\/ajg.2009.410","volume":"104","author":"Cassinotti A.","year":"2009","unstructured":"Cassinotti A.; Actis G.C.; Duca P.; Maintenance treatment with azathioprine in ulcerative colitis: Outcome and predictive factors after drug withdrawal. Am J Gastroenterol  2009,104(11),2760-2767","journal-title":"Am J Gastroenterol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5217\/ir.2020.00155","volume":"20","author":"Singh A.","year":"2022","unstructured":"Singh A.; Mahajan R.; Kedia S.; Use of thiopurines in inflammatory bowel disease: An update. Intest Res  2022,20(1),11-30","journal-title":"Intest Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1515\/jbcpp-2016-0014","volume":"29","author":"Ahmad H.","year":"2018","unstructured":"Ahmad H.; Kumar V.L.; Pharmacotherapy of ulcerative colitis \u2013 current status and emerging trends. J Basic Clin Physiol Pharmacol  2018,29(6),581-592","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1756283X09354136","volume":"3","author":"Ardizzone S.","year":"2010","unstructured":"Ardizzone S.; Cassinotti A.; Manes G.; Porro G.; Review: Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol  2010,3(1),31-42","journal-title":"Therap Adv Gastroenterol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00535-010-0352-z","volume":"46","author":"Naganuma M.","year":"2011","unstructured":"Naganuma M.; Fujii T.; Watanabe M.; The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol  2011,46(2),129-137","journal-title":"J Gastroenterol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/ibd.21318","volume":"16","author":"Yoshino T.","year":"2010","unstructured":"Yoshino T.; Nakase H.; Honzawa Y.; Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis  2010,16(12),2022-2033","journal-title":"Inflamm Bowel Dis"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","volume":"2","author":"L\u00e9ia C.R.S.","year":"2010","unstructured":"L\u00e9ia C.R.S.; Luciena C.M.O.; Gil B.; Anti-TNF-(alpha) agents in the treatment of immune-mediated inflammatory diseases: Mechanisms of action and pitfalls. Immunotherapy  2010,2(6),817-833","journal-title":"Immunotherapy"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/jpe\/rtab100","volume":"15","author":"Li J.","year":"2022","unstructured":"Li J.; Leng Z.; Wu Y.; Interactions between invasive plants and heavy metal stresses: a review. J Plant Ecol  2022,15(3),429-436","journal-title":"J Plant Ecol"},{"key":"ref=69","first-page":"163","volume":"7","author":"Gilroy L.","year":"2014","unstructured":"Gilroy L.; Allen P.B.; Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn\u2019s disease? Clin Exp Gastroenterol  2014,7(1),163-172","journal-title":"Clin Exp Gastroenterol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","volume":"8","author":"Cai Z.","year":"2021","unstructured":"Cai Z.; Wang S.; Li J.; Treatment of inflammatory bowel disease: A comprehensive review. Front Med  2021,8,765474","journal-title":"Front Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/11632710-000000000-00000","volume":"72","author":"Jonkers D.","year":"2012","unstructured":"Jonkers D.; Penders J.; Masclee A.; Pierik M.; Probiotics in the management of inflammatory bowel disease: A systematic review of intervention studies in adult patients. Drugs  2012,72(6),803-823","journal-title":"Drugs"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3748\/wjg.v29.i14.2078","volume":"29","author":"Roy S.","year":"2023","unstructured":"Roy S.; Dhaneshwar S.; Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol  2023,29(14),2078-2100","journal-title":"World J Gastroenterol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","volume":"20","author":"Langedijk J.","year":"2015","unstructured":"Langedijk J.; Mantel-Teeuwisse A.K.; Slijkerman D.S.; Schutjens M.H.D.B.; Drug repositioning and repurposing: Terminology and definitions in literature. Drug Discov Today  2015,20(8),1027-1034","journal-title":"Drug Discov Today"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/B978-0-12-386009-5.00004-7","volume":"46","author":"Doan T.L.","year":"2011","unstructured":"Doan T.L.; Pollastri M.; Walters M.A.; Georg G.I.; The future of drug repositioning. Annu Rep Med Chem  2011,46,385-401","journal-title":"Annu Rep Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1021\/acs.jafc.0c06755","volume":"69","author":"Wang X.","year":"2021","unstructured":"Wang X.; Gao Y.; Wang L.; Troxerutin improves dextran sulfate sodium-induced ulcerative colitis in mice. J Agric Food Chem  2021,69(9),2729-2744","journal-title":"J Agric Food Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.3389\/fimmu.2018.02119","volume":"9","author":"Schirmer B.","year":"2018","unstructured":"Schirmer B.; Bringmann L.; Seifert R.; Neumann D.; In vivo evidence for partial activation of eosinophils via the histamine H4-receptor: Adoptive transfer experiments using eosinophils from H4R-\/- and H4R+\/+ mice. Front Immunol  2018,9,2119","journal-title":"Front Immunol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bcp.2015.06.030","volume":"97","author":"Wang X.","year":"2015","unstructured":"Wang X.; Wang S.; Hu C.; A new pharmacological effect of levornidazole: Inhibition of NLRP3 inflammasome activation. Biochem Pharmacol  2015,97(2),178-188","journal-title":"Biochem Pharmacol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1034\/j.1600-0773.2002.910104.x","volume":"91","author":"Mendes A.F.","year":"2002","unstructured":"Mendes A.F.; Caramona M.M.; De Carvalho A.P.; Lopes M.C.; Diacerhein and rhein prevent interleukin-1\u03b2-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-\u03b1. Pharmacol Toxicol  2002,91(1),22-28","journal-title":"Pharmacol Toxicol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"110594","DOI":"10.1016\/j.biopha.2020.110594","volume":"131","author":"Almezgagi M.","year":"2020","unstructured":"Almezgagi M.; Zhang Y.; Hezam K.; Diacerein: Recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother  2020,131,110594","journal-title":"Biomed Pharmacother"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"113651","DOI":"10.1016\/j.biopha.2022.113651","volume":"154","author":"Zohny M.H.","year":"2022","unstructured":"Zohny M.H.; Alrouji M.; Alhajlah S.; Diacetylrhein, an anthraquinone antiarthritic agent, suppresses dextran sodium sulfate-induced inflammation in rats: A possible mechanism for a protective effect against ulcerative colitis. Biomed Pharmacother  2022,154,113651","journal-title":"Biomed Pharmacother"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-30-87","volume":"30","author":"Wong R.S.Y.","year":"2011","unstructured":"Wong R.S.Y.; Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res  2011,30(1),87","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/1574885517666220328142715","volume":"17","author":"Roy S.","year":"2022","unstructured":"Roy S.; Dhaneshwar S.; Mahmood T.; Exploring the potential of il-1\u03b2 inhibitor diacerein and its combination with 5-aminosalicylic acid for the possible ameliorating effect in tnbsinduced experimental colitis in wistar rats. Curr Drug Ther  2022,17(2),132-146","journal-title":"Curr Drug Ther"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"107710","DOI":"10.1016\/j.pharmthera.2020.107710","volume":"219","author":"Russo C.","year":"2021","unstructured":"Russo C.; Scott K.A.; Pirmohamed M.; Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature. Pharmacol Ther  2021,219,107710","journal-title":"Pharmacol Ther"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40265-017-0854-6","volume":"78","author":"Blair H.A.","year":"2018","unstructured":"Blair H.A.; Dimethyl fumarate: A review in moderate to severe plaque psoriasis. Drugs  2018,78(1),123-130","journal-title":"Drugs"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"Linker R.A.","year":"2011","unstructured":"Linker R.A.; Lee D.H.; Ryan S.; Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain  2011,134(3),678-692","journal-title":"Brain"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fneur.2018.00005","volume":"9","author":"Mills E.A.","year":"2018","unstructured":"Mills E.A.; Ogrodnik M.A.; Plave A.; Mao-Draayer Y.; Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol  2018,9(JAN),5","journal-title":"Front Neurol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.medidd.2022.100142","volume":"16","author":"Patel V.","year":"2022","unstructured":"Patel V.; Joharapurkar A.; Kshirsagar S.; Repurposing dimethyl fumarate for gastric ulcer and ulcerative colitis: Evidence of local efficacy without systemic side effect. Med in Drug Discov  2022,16,100142","journal-title":"Med in Drug Discov"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ph13050095","volume":"13","author":"Asatsuma-Okumura T.","year":"2020","unstructured":"Asatsuma-Okumura T.; Ito T.; Handa H.; Molecular mechanisms of the teratogenic effects of thalidomide. Pharmaceuticals  2020,13(5),95","journal-title":"Pharmaceuticals"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1111\/cas.14538","volume":"111","author":"Miyazato K.","year":"2020","unstructured":"Miyazato K.; Tahara H.; Hayakawa Y.; Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells. Cancer Sci  2020,111(8),2770-2778","journal-title":"Cancer Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-4632.2004.02445.x","volume":"44","author":"Faver I.R.","year":"2005","unstructured":"Faver I.R.; Guerra S.G.; Su W.P.D.; el-Azhary R.; Thalidomide for dermatology: A review of clinical uses and adverse effects. Int J Dermatol  2005,44(1),61-67","journal-title":"Int J Dermatol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdrc.21096","volume":"105","author":"Vargesson N.","year":"2015","unstructured":"Vargesson N.; Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today  2015,105(2),140-156","journal-title":"Birth Defects Res C Embryo Today"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2183\/pjab.96.016","volume":"96","author":"Ito T.","year":"2020","unstructured":"Ito T.; Handa H.; Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad, Ser B  2020,96(6),189-203","journal-title":"Proc Jpn Acad, Ser B"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"Holstein S.A.","year":"2017","unstructured":"Holstein S.A.; McCarthy P.L.; Immunomodulatory drugs in multiple myeloma: Mechanisms of action and clinical experience. Drugs  2017,77(5),505-520","journal-title":"Drugs"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/dmd.108.024679","volume":"37","author":"Okada Y.","year":"2009","unstructured":"Okada Y.; Murayama N.; Yanagida C.; Shimizu M.; Guengerich F.P.; Yamazaki H.; Drug interactions of thalidomide with midazolam and cyclosporine A: Heterotropic cooperativity of human cytochrome P450 3A5. Drug Metab Dispos  2009,37(1),18-23","journal-title":"Drug Metab Dispos"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"e4239","DOI":"10.1097\/MD.0000000000004239","volume":"95","author":"Bramuzzo M.","year":"2016","unstructured":"Bramuzzo M.; Ventura A.; Martelossi S.; Lazzerini M.; Thalidomide for inflammatory bowel disease. Medicine  2016,95(30),e4239","journal-title":"Medicine"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3748\/wjg.v13.i15.2166","volume":"13","author":"Carvalho A.T.","year":"2007","unstructured":"Carvalho A.T.; Souza H.; Carneiro A.J.; Therapeutic and prophylactic thalidomide in TNBS-induced colitis: Synergistic effects on TNF-\u03b1 IL-12 and VEGF production. World J Gastroenterol  2007,13(15),2166-2173","journal-title":"World J Gastroenterol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1053\/j.gastro.2014.01.015","volume":"146","author":"Avitzur Y.","year":"2014","unstructured":"Avitzur Y.; Guo C.; Mastropaolo L.A.; Mutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease. Gastroenterology  2014,146(4),1028-1039","journal-title":"Gastroenterology"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1172\/JCI71471","volume":"124","author":"Bigorgne A.E.","year":"2014","unstructured":"Bigorgne A.E.; Farin H.F.; Lemoine R.; TTC7A mutations disrupt intestinal epithelial apicobasal polarity. J Clin Invest  2014,124(1),328-337","journal-title":"J Clin Invest"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jcmgh.2018.12.001","volume":"7","author":"Jardine S.","year":"2019","unstructured":"Jardine S.; Dhingani N.; Muise A.M.; TTC7A: Steward of intestinal health. Cell Mol Gastroenterol Hepatol  2019,7(3),555-570","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3389\/fimmu.2017.01066","volume":"8","author":"Lien R.","year":"2017","unstructured":"Lien R.; Lin Y.F.; Lai M.W.; Novel mutations of the tetratricopeptide repeat domain 7a gene and phenotype\/genotype comparison. Front Immunol  2017,8,1066","journal-title":"Front Immunol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/(SICI)1521-1878(199911)21:11<932:AID-BIES5>3.0.CO;2-N","volume":"21","author":"Blatch G.L.","year":"1999","unstructured":"Blatch G.L.; L\u00e4ssle M.; The tetratricopeptide repeat: A structural motif mediating protein-protein interactions. BioEssays  1999,21(11),932-939","journal-title":"BioEssays"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1053\/j.gastro.2019.11.019","volume":"158","author":"Jardine S.","year":"2020","unstructured":"Jardine S.; Anderson S.; Babcock S.; Leung G.; Pan J.; Dhingani N.; Drug screen identifies leflunomide for treatment of inflammatory bowel disease caused by TTC7A deficiency. Gastroenterology  2020,158(4),1000-1015","journal-title":"Gastroenterology"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/ard.59.11.841","volume":"59","author":"Breedveld F.C.","year":"2000","unstructured":"Breedveld F.C.; Dayer J.M.; Leflunomide: Mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis  2000,59(11),841-849","journal-title":"Ann Rheum Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"651415","DOI":"10.3389\/fphar.2021.651415","volume":"12","author":"Al-Bawardy B.","year":"2021","unstructured":"Al-Bawardy B.; Shivashankar R.; Proctor D.D.; Novel and emerging therapies for inflammatory bowel disease. Front Pharmacol  2021,12,651415","journal-title":"Front Pharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.3748\/wjg.v16.i44.5523","volume":"16","author":"De Winter B.Y.","year":"2010","unstructured":"De Winter B.Y.; De Man J.G.; Interplay between inflammation, immune system and neuronal pathways: Effect on gastrointestinal motility. World J Gastroenterol  2010,16(44),5523-5535","journal-title":"World J Gastroenterol"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1684\/j.1950-6945.2003.tb00006.x","volume":"5","author":"Bumb A.","year":"2003","unstructured":"Bumb A.; Diederich N.; Beyenburg S.; Adding topiramate to valproate therapy may cause reversible hepatic failure. Epileptic Disord  2003,5(3),157-159","journal-title":"Epileptic Disord"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/ecco-jcc\/jjx075","volume":"11","author":"Stremmel W.","year":"2017","unstructured":"Stremmel W.; Staffer S.; Schneider M.J.; Genetic mouse models with intestinal-specific tight junction deletion resemble an ulcerative colitis phenotype. J Crohn\u2019s Colitis  2017,11(10),1247-1257","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.3748\/wjg.v24.i33.3681","volume":"24","author":"Mumolo M.G.","year":"2018","unstructured":"Mumolo M.G.; Bertani L.; Ceccarelli L.; From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol  2018,24(33),3681-3694","journal-title":"World J Gastroenterol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"9127","DOI":"10.3390\/ijms23169127","volume":"23","author":"Silva I.","year":"2022","unstructured":"Silva I.; Mendes P.; Guerra S.; Pinto R.; Mateus V.; Anti-inflammatory effect of topiramate in a chronic model of TNBS-induced colitis. Int J Mol Sci  2022,23(16),9127","journal-title":"Int J Mol Sci"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1002\/med.21837","volume":"41","author":"Meng Y.","year":"2021","unstructured":"Meng Y.; Ma N.; Lyu H.; Recent pharmacological advances in the repurposing of artemisinin drugs. Med Res Rev  2021,41(6),3156-3181","journal-title":"Med Res Rev"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3892\/mmr.2019.10345","volume":"20","author":"Chen Y.X.","year":"2019","unstructured":"Chen Y.X.; Zhang X.Q.; Yu C.G.; Artesunate exerts protective effects against ulcerative colitis via suppressing Toll like receptor 4 and its downstream nuclear factor -\u03baB signaling pathways. Mol Med Rep  2019,20(2),1321-1332","journal-title":"Mol Med Rep"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/aps.2017.185","volume":"39","author":"Yan Y.X.","year":"2018","unstructured":"Yan Y.X.; Shao M.J.; Qi Q.; Xu Y.S.; Yang X.Q.; Zhu F.H.; Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages. Acta Pharmacol Sin  2018,39(10),1633-1644","journal-title":"Acta Pharmacol Sin"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/1535370218769420","volume":"243","author":"Ge X.","year":"2018","unstructured":"Ge X.; Chen Z.; Xu Z.; Lv F.; Zhang K.; Yang Y.; The effects of dihydroartemisinin on inflammatory bowel disease-related bone loss in a rat model. Exp Biol Med  2018,243(8),715-724","journal-title":"Exp Biol Med"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.3390\/molecules24132475","volume":"24","author":"Si C.Y.","year":"2019","unstructured":"Si C.Y.; Ya J.W.; Yu J.L.; Dihydroartemisinin regulates the th\/treg balance by inducing activated CD4+ T cell apoptosis via heme oxygenase-1 induction in mouse models of inflammatory bowel disease. Molecules  2019,24(13),2475","journal-title":"Molecules"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/0006-291X(77)90981-0","volume":"76","author":"Horrobin D.F.","year":"1977","unstructured":"Horrobin D.F.; Manku M.S.; Karmazyn M.; Ally A.I.; Morgan R.O.; Karmali R.A.; Quinacrine is a prostaglandin antagonist. Biochem Biophys Res Commun  1977,76,1188-1193","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1007\/s11033-014-3707-3","volume":"41","author":"Kara M.","year":"2014","unstructured":"Kara M.; Yumrutas O.; Atilgan R.; Baspinar M.; Sapmaz E.; Kuloglu T.; Expression changes of antioxidant, apoptotic, anti-apoptotic genes and miR-15b-34a-21-98 in over tissue by using erythromycin, quinacrine and tetracycline in non-surgical sterilization. Mol Biol Rep  2014,41(12),8093-8098","journal-title":"Mol Biol Rep"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1478-811X-9-13","volume":"9","author":"Ehsanian R.","year":"2011","unstructured":"Ehsanian R.; Van Waes C.; Feller S.M.; Beyond DNA binding - a review of the potential mechanisms mediating quinacrine\u2019s therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal  2011,9(1),13","journal-title":"Cell Commun Signal"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/hep.23035","volume":"50","author":"Zeitz J.","year":"2009","unstructured":"Zeitz J.; Mullhaupt B.; Fruehauf H.; Rogler G.; Vavricka S.R.; Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology  2009,50(2),653-654","journal-title":"Hepatology"},{"key":"ref=119","first-page":"81","volume":"20","author":"Mohapatra P.","year":"2012","unstructured":"Mohapatra P.; Preet R.; Das D.; Quinacrine-mediated autophagy and apoptosis in colon cancer cells is through a p53-and p21-dependent mechanism. Oncol Res Featur Preclin Clin Cancer Ther  2012,20,81-91","journal-title":"Oncol Res Featur Preclin Clin Cancer Ther"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1093\/jamia\/ocab165","volume":"28","author":"Bai L.","year":"2021","unstructured":"Bai L.; Scott M.K.D.; Steinberg E.; Computational drug repositioning of atorvastatin for ulcerative colitis. J Am Med Inform Assoc  2021,28(11),2325-2335","journal-title":"J Am Med Inform Assoc"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12664-013-0420-4","volume":"33","author":"Dhamija P.","year":"2014","unstructured":"Dhamija P.; Hota D.; Kochhar R.; Sachdev A.; Chakrabarti A.; Randomized clinical trial: Atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis. Indian J Gastroenterol  2014,33(2),151-156","journal-title":"Indian J Gastroenterol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"e5263","DOI":"10.1371\/journal.pone.0005263","volume":"4","author":"Grip O.","year":"2009","unstructured":"Grip O.; Janciauskiene S.; Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn\u2019s disease. PLoS One  2009,4(5),e5263","journal-title":"PLoS One"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00005176-200203000-00005","volume":"34","author":"Ruemmele F.M.","year":"2002","unstructured":"Ruemmele F.M.; Seidman E.G.; Lentze M.J.; Regulation of intestinal epithelial cell apoptosis and the pathogenesis of inflammatory bowel disorders. J Pediatr Gastroenterol Nutr  2002,34(3),254-260","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","volume":"363","author":"McCarey D.W.","year":"2004","unstructured":"McCarey D.W.; McInnes I.B.; Madhok R.; Trial of atorvastatin in rheumatoid arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet  2004,363(9426),2015-2021","journal-title":"Lancet"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1773-2247(11)50085-1","volume":"21","author":"Dhaneshwar S.S.","year":"2011","unstructured":"Dhaneshwar S.S.; Sharma M.; Vadnerkar G.; Co-drugs of aminosalicylates and nutraceutical amino sugar for ulcerative colitis. J Drug Deliv Sci Technol  2011,21(6),527-533","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.1038\/s41598-018-24050-6","volume":"8","author":"Li Y.","year":"2018","unstructured":"Li Y.; Chen L.; Liu Y.; Zhang Y.; Liang Y.; Mei Y.; Anti-inflammatory effects in a mouse osteoarthritis model of a mixture of glucosamine and chitooligosaccharides produced by bi-enzyme single-step hydrolysis. Sci Rep  2018,8(1),5624","journal-title":"Sci Rep"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/08923973.2022.2128370","volume":"45","author":"Roy S.","year":"2022","unstructured":"Roy S.; Dhaneshwar S.; Mahmood T.; Kumar S.; Saxena S.K.; Pre-clinical investigation of protective effect of nutraceutical D-glucosamine on TNBS-induced colitis. Immunopharmacol Immunotoxicol  2022,45(2),172-184","journal-title":"Immunopharmacol Immunotoxicol"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328245156231008154045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/222303\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328245156231008154045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T08:09:53Z","timestamp":1712218193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/222303\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724328245156231008154045","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}